Open AccessA Case with <sup>68</sup>Ga-FAPI Positive and <sup>18</sup>F-FDG Negative Breast Cancer
Author(s) -
Halil Kömek,
Cihan Gündoğan,
Hülya Etem,
Canan Can
Publication year - 2021
Publication title -
molecular imaging and radionuclide therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.292
H-Index - 7
eISSN - 2147-1959
pISSN - 2146-1414
DOI - 10.4274/mirt.galenos.2021.69926
Subject(s) - medicine , nuclear medicine , fibroblast activation protein, alpha , pet ct , breast cancer , positron emission tomography , positron emission tomography computed tomography , radiology , cancer
A female patient diagnosed of infiltrative breast carcinoma using tru-cut biopsy underwent 18 flourine-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for staging. The tumor was located in the superior external quadrant of the right breast, and did not exhibit pathological uptake in 18 F-FDG PET/CT. Later, gallium- 68 ( 68 Ga) fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT imaging was performed and the primary tumor showed intense radiotracer accumulation. This presumes that 68 Ga-FAPI PET/CT imaging is superior to 18 F-FDG imaging in detecting the primary tumor in breast cancer, thereby suggesting the replacement of FAPI by 18 F-FDG in breast-cancer staging in the future.